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Abstract 
The interaction of human CK2α (hCK2α) with nine halogenated benzotriazoles, TBBt and 
its analogs representing all possible patterns of halogenation on the benzene ring of 
benzotriazole, was studied by biophysical methods. Thermal stability of protein–ligand 
complexes, monitored by calorimetric (DSC) and optical (DSF) methods, showed that the 
increase in the mid-point temperature for unfolding of protein-ligand complexes (i.e. potency 
of ligand binding to hCK2α) follow the inhibitory activities determined by biochemical 
assays.  
The dissociation constant for the ATP-hCK2α complex was estimated with the aid of 
Microscale Thermophoresis (MST) as 4.3±1.8 µM, and MST-derived dissociation constants 
determined for halogenated benzotriazoles, when converted according to known ATP 
concentrations, perfectly reconstruct IC50 values determined by the biochemical assays.  
Ligand-dependent quenching of tyrosine fluorescence, together with molecular modeling 
and DSC-derived heats of unfolding, support the hypothesis that halogenated benzotriazoles 
bind in at least two alternative orientations, and those that are efficient hCK2α inhibitors bind 
in the orientation which TBBt adopts in its complex with maize CK2α.  
DSC-derived apparent heat for ligand binding (ΔΔHbind) is driven by intermolecular 
electrostatic interactions between Lys68 and the triazole ring of the ligand, as indicated by a 
good correlation between ΔΔHbind and ligand pKa. Overall results, additionally supported by 
molecular modeling, confirm that a balance of hydrophobic and electrostatic interactions 
contribute predominantly (~40 kJ/mol), relative to possible intermolecular halogen/hydrogen 
bonding (less than 10 kJ/mol), in binding of halogenated benzotriazoles to the ATP-binding 
site of hCK2α. 
 
 
 
 
 
 
Abreviations: 
hCK2a – catalytic subunit of human casein kinase II; 
DSC – differential scanning calorimetry; 
DSF – differential scanning fluorimetry; 
MST – microscale thermophoresis; 
PDB – Protein Data Bank;
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1. Introduction 
Cellular growth and division is driven by (ir)reversible post-translational modifications 
(phosphorylation, glycosylation, ubiquitination, S-nitrosylation, methylation, N-acetylation, 
lipidation, proteolysis) and numerous nonbonding interactions with other constituents 
(proteins, nucleic acids, lipids, metal ions, cofactors), as well as interactions with solvent 
molecules [1-4]. However, specific non-covalent interactions with low-mass ligands are also 
of considerable importance.  
Van der Waals interactions, both attractive and repulsive, are short-range interactions that 
control the majority of binding events [5]. Spatial compatibility directs ligand selectivity, 
excluding most putative ligands, and favoring those that fit to the protein binding site. Van 
der Waals interactions are relatively weak (0.1- 4 kJ/mol), when compared to other non-
covalent interactions, albeit the large number of contacts created upon molecular recognition 
makes their contribution to the Gibbs' free energy of interaction significant, the maximum of 
which is attained when the shapes of ligand and protein binding site are complementary. This 
corresponds to the Lock and Key analogy originally postulated in 1894 by Emil Fischer, and 
further extended to the Induced-Fit Theory, describing dynamic changes of protein structure 
upon ligand binding (see [6] for review). Basically, binding events occur when they are 
accompanied by a decrease of Gibbs' free energy of binding (ΔG), resulting from a balance 
between entropic (-TΔS) and enthalpic (ΔH) components. It should be stressed that 
notwithstanding direct protein-ligand interactions, solvent molecules, surrounding both in free 
and bound states, may also contribute substantially to changes of these thermodynamic 
parameters. Other medium- and long-range interactions are generally associated with electron 
densities distributed on the interacting species. The strongest occur between charged groups, 
known as salt-bridges [7], the contribution of which, to the Gibbs' free energy, approaches 40 
kJ/mol [8]. The next terms describe charge-dipole, dipole-dipole and higher-order 
interactions, which decrease more rapidly with the distance between components. 
Hydrogen bonds contribute significantly to the organization of intermolecular complexes. 
The energy of a single hydrogen bond (H-bond) in protein-ligand complexes depends both on 
the type of hydrogen bond donor (D) and acceptor (A) pairs, and on the overall geometry of 
the D-H∙∙∙A system [9], varying in a range of 5 to 20 kJ/mol. Subsequently, numerous non-
canonical weak H-bonds have been identified by statistical analyses of protein structures, 
including a π-electron system acting as an H-bond acceptor [10-12], and an aliphatic carbon 
acting as an H-bond donor [11, 13-15]. 
During the past decade, halogen bonding (X-bond, see [16] for review) has been identified 
as an alternative to H-bonding in many crystal structures of low-mass ligands and their 
possible supramolecular ensembles [16-27], as well as in complexes of biomolecules with 
halogenated ligands [28-30]. The role of halogenated ligands in biological systems has been 
 4 
widely reviewed, amongst others, by Auffinger et al. [28], Parisini et al. [31], Rendine et al. 
[30], Voth & Ho [32], Voth et al. [33], Scholfield et al. [34], Wilcken et al. [35] and 
Poznański & Shugar [36]. However, the thermodynamic contribution of a halogen bond is 
still under debate [27, 32, 37-47], estimates of which vary from 0.8 [44] up to 30 kJ/mol [32]. 
Numerous natural drugs and an increasing number of synthetic drug candidates are 
halogenated [48-50], and comprise almost 20% of low-mass protein ligands accessible in the 
Protein Data Bank (PDB) [47]. Consequently, understanding the thermodynamics of ligand 
binding, including the possible contribution of halogen bonding, should support rational drug 
design of halogenated compounds. 
Protein kinase CK2 was selected as a model protein. It is a constitutively active Ser/Thr 
protein kinase that regulates hundreds of independent cellular processes - more than 300 
protein substrates have been identified [51]. CK2 has become a therapeutic target for 
inhibitors directed to cancer treatment [52, 53] because of the strong correlation between 
malignancy and an abnormally high activity of CK2 in cancer cells [54]. An increasing 
number of high-resolution structures of CK2-ligand complexes help in the in-silico 
development of new CK2 inhibitors [55] - many of them halogenated.  
4,5,6,7-tetrabromo-1H-benzotriazole (TBBt, Scheme 1) is an ATP-competitive inhibitor 
displaying reasonable selectivity for CK2 and its catalytic subunit CK2α [52, 53], which 
target the ATP-binding site [56, 57]. More potent inhibitors have since been reported, many 
of them designed as TBBt analogues [58, 59].  
Analysis of a series of nine benzotriazoles brominated on the benzene ring clearly showed 
that their inhibitory activity against CK2α is strongly correlated with their physico-chemical 
properties (aqueous solubility, molecular volume, pKa for dissociation of the triazole proton) 
[60, 61]. We have also shown that a balance of hydrophobic and electrostatic interactions, 
with an eventual possible contribution of halogen bonding, drive inhibitory activities of 
benzotriazoles halogenated on the benzene ring [60-63]. 
There are numerous data concerning individual ligands, but only few reports concerning 
screening tests for binding of low-mass ligands by protein kinases [64-70]. And only limited 
data concern systematic thermodynamic studies on a series of closely related substrate-
mimicking peptides [71-73] or low-mass ligands [74, 75]. Herein, we analyze the activity of 
TBBt and some close analogues, in which selected bromine atoms are replaced by hydrogen, 
in terms of thermodynamic parameters describing protein-ligand interactions obtained by 
optical (differential scanning fluorimetry, DSF) and calorimetric (differential scanning 
calorimetry, DSC) methods. Stability constants for the seven most potent ligands were 
additionally estimated at 25 °C by Microscale Thermophoresis (MST).  
 
2. Materials and Methods 
2.1. Synthetic Procedures 
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All reagents and solvents were purchased from Sigma Aldrich, Chempur, Avantor and 
Merck. Thin-layer chromatography (TLC) was performed on 0.2 mm Merck silica gel 60 
F254 plates, and column chromatography with Merck silica gel 60 (230 – 400 mesh).  
All brominated ligands (Scheme 1) were prepared according to previously reported 
procedures [60, 62]. 13C NMR and Mass spectra for the final compounds are consistent with 
those reported originally [60, 62]. In some cases the procedures were further optimized (see 
Supplementary Materials for details).  
 
NH (1)
N (2)
N (3)
R (7)
R (6)
R (5)
R (4)
4-BrBt              R(4) - Br; R(5), R(6), R(7) - H
5-BrBt              R(5) - Br; R(4), R(6), R(7) - H
4,5-Br 2Bt          R(4), R(5) - Br; R(6), R(7) - H
4,6-Br 2Bt          R(4), R(6) - Br; R(5), R(7) - H
4,7-Br 2Bt          R(4), R(7) - Br; R(5), R(6) - H
5,6-Br 2Bt          R(5), R(6) - Br; R(4), R(7) - H
4,5,6-Br3Bt       R(4), R(5), R(6) - Br;  R(7) - H
4,5,7-Br3Bt       R(4), R(5), R(7) - Br;  R(5) - H
TBBt                R(4), R(5), R(6), R(7) - Br    
Scheme 1. All possible benzotriazole derivatives halogenated on the benzene ring 
  
4-bromo-1H-benzotriazole (4-BrBt) was obtained from 2,1,3-benzothiadiazole by selective 
bromination [79], followed by reductive sulfur extrusion [81] and diazotization with NaNO2 
[63]. 
5-Bromo-1H-benzotriazole (5-BrBt) was prepared from 4-bromo-o-phenylenediamine by 
diazotization with NaNO2 [63].  
4,5-Dibromo-1H-benzotriazole (4,5-Br2Bt) was prepared by bromination of commercially 
available 5-bromo-2,1,3-benzothiadiazole [79], followed by reductive sulfur extrusion [81] 
and diazotization [63].  
4,6-Dibromo-1H-benzotriazole (4,6-Br2Bt) was prepared by reduction of 2,4-dibromo-6-
nitroaniline with SnCl2 [63]. The crude 3,5-dibromo-o-phenylenediamine dihydrochloride was 
then reacted with NaNO2 to give the desired product [63]. 
4,7-dibromo-1H-benzotriazole (4,7-Br2Bt). Selective bromination of 2,1,3-
benzothiadiazole [79] obtained from commercially available o-phenylenodiamine [80], 
followed by reductive sulfur extrusion [81] and diazotization with NaNO2 [63] gave the 
desired product. 
5,6-Dibromo-1H-benzotriazole (5,6-Br2Bt) was prepared by bromination of o-
phenylenediamine (amine groups protected with p-toluenesulphonyl chloride [77]) followed 
by deprotection with concentrated H2SO4 and diazotization with NaNO2 [63]. 
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4,5,6-Tribromo-1H-benzotriazole (4,5,6-Br3Bt). Nitration of commercially available 1,2,3-
tribromo-5-nitrobenzene [60], followed by reduction and diazotization [63], gave the desired 
product.  
4,5,7-Tribromo-1H-benzotriazole (4,5,7-Br3Bt). After bromination of commercially 
available 5-methyl-1H-benzotriazole [78], the methyl group was oxidized with KMnO4, and 
the carboxyl group was removed by reaction with quinoline [62].  
4,5,6,7-Tetrabromo-1H-benzotriazole (TBBt) was prepared from 1H-benzotriazole [76]. 
 
2.2. Expression and purification of hCK2α 
Plasmid pET28 containing DNA encoding human CK2α subunit (kindly provided by the 
Laboratory of RNA Biology and Functional Genomics IBB PAN) was transformed into 
BL21(DE3) E. coli cells. A single colony was inoculated in 30 ml LB broth supplemented 
with kanamycin (50 µg/ml) and incubated overnight at 37 ºC. The culture (5 ml) was used to 
inoculate 1000 ml of Luria Broth with kanamycin (50 µg/ml) and cells were cultured at 37 °C 
until OD600 reached 0.5, when hCK2α expression was induced by 0.5 mM Isopropylthio-β-
galactoside. Cells were then incubated at 37 ºC for 4 hours, harvested by centrifugation at 
6000 rpm for 10 min at 4 ºC, and stored at -20 ºC.  
Thawed cells were suspended in 30 ml of buffer A (25 mM Tris-HCl pH 8, 500 mM NaCl, 
10 mM imidazole, 5 mM β-mercaptoethanol) with 0.2 mM PMSF (phenylmethylsulfonyl 
fluoride) and protease inhibitor cocktail (Sigma-Aldrich P8849), and sonicated by five 1-min 
bursts. The cell lysate was centrifuged at 20000 rpm for 40 min, and the supernatant fraction 
processed by Ni2+-NTA agarose chromatography under non-denaturing conditions. The 
protein was then purified by affinity chromatography with a HiTrap Heparin HP column (GE 
HealthCare), and eluted with a linear 0.4 to 1 M NaCl gradient buffered with 25 mM Tris-
HCl, pH 8.5. Purified (His)6-tagged hCK2α was concentrated by ultrafiltration, rebuffered in 
500 mM NaCl, 50% glycerol, 1 mM DTT, 25 mM Tris-HCl, pH 8.5, and stored at -80 °C. 
The final yield of purified protein was 20 mg/l. Concentration of purified protein was 
estimated by UV absorbance at 280 nm, assuming a molar extinction coefficient ε = 61895 M-
1cm-1. Protein purity was further checked by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis.  
2.3. Sample preparation.  
In all experiments hCK2α was diluted with 25 mM Tris-HCl (pH 8, 0.5 M NaCl) to the 
required protein concentration. In fluorescence and MST experiments the buffer contained 
additionally 5 mM β-mercapthoethanol.  
All ligands were initially dissolved in dimethyl sulfoxide (DMSO), and the appropriate 
amounts of ligand stock solutions were diluted with DMSO prior to addition to the protein 
samples to obtain the required ligand concentration with a final DMSO concentration of 2%. 
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2.4. Molecular Modeling of the complex of TBBt with human CK2α. 
The ensemble of seven structures was modeled by homology, based on the highest-
resolution structures of human CK2α found in the Protein Data Bank (PDB: 3at2 [82], 3bqc 
[83], 3h30 [84], 3nsz [85], 3pe1 [86], 3war [87], 4kwp [88]). Each was then structurally 
aligned with the complex of TBBt with maize CK2α (PDB: 1j91 [57]), using the Mustang 
algorithm [89] implemented in the Yasara Structure Package [90]. The location of the TBBt 
ligand was then adopted directly from its complex with maize CK2α, and the resulting 
structures of the complex were tuned by 1 ns Molecular Dynamics with all residues located 
outside a 10 Å sphere centered at TBBt kept fixed. Alternative binding orientations for TBBt 
were analogously adopted (without MD-tuning) from the complexes of maize CK2α with 
4,5,6,7-tetrabromo-1H-benzimidazole (PDB: 2oxy [91]) and 3,4,5,6,7-pentabromo-1H-
indazole (PDB: 3kxg [53]), which are the closest structural analogues of TBBt. 
2.5. Differential scanning fluorimetry (DSF) 
Fluorescence data were collected on a Varian Cary Eclipse spectroﬂuorometer, equipped 
with a constant-temperature cell holder, using 10-mm path-length cuvettes. Protein emission 
was monitored at 335 nm (excitation at 280 nm) at temperatures of 20 to 80 ºC, with 1 ºC/min 
heating rate. The protein (hCK2α) was diluted to a final concentration of 0.25 μM (see 
Section 2.3).  
All the numerical models were individually fitted to experimental data, assuming a two-
state cooperative transition at Tm, using the Marquardt algorithm [92] implemented in the 
GnuPlot program [93] according to Equation 1.  
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where p mimics the slope of I(T) at Tm, and IF(T) and IU(T) are linear approximates of the 
temperature-dependence of fluorescence intensities of the folded (F) and unfolded (U) states, 
respectively. The final results (see Table 1) are weighted-averages from at least 5 independent 
experiments. 
2.6. Differential scanning calorimetry (DSC) 
All measurements were carried on a Nano DSC differential scanning calorimeter (TA 
Instruments) equipped with cells of 300 μL volume (both sample and reference). A pressure 
of 3 atm was applied to prevent solvent vaporization upon heating. Protein thermal 
denaturation was followed by the heat flow accompanying variations in the sample heat 
capacity. The temperature was varied in the range 20-80 ºC (scan rate of 1 ºC/min). The 
protein concentration was 0.25 mg/ml (5.43 µM), and appropriate DMSO solutions of ligands 
were added to obtain a 1:1 ligand to protein molar ratio with a final DMSO concentration of 
2% (v:v). All experiments were repeated at least 2 times. Base-line correction, heat effect 
determined by peak integration, and estimates of temperature of unfolding (Tm) were done 
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using the NanoAnalyze Data Analysis software (TA instruments). Further extrapolations of 
ΔG to 25 ºC were done according to Equation 2 [94]: 
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where a change in the heat capacity upon unfolding (ΔCp) was assumed temperature-
independent, and the value of which, at Tm, was roughly estimated from heat-flow 
thermograms as the difference between high- and low-temperature asymptotes at Tm. Entropy, 
enthalpy and free energy for ligand binding were then calculated as the difference between 
appropriate thermodynamic parameters estimated separately for free and ligand-bound 
protein. 
2.7. Microscale thermophoresis (MST) 
The hCK2α was initially labeled with the commercially available NT-647 dye, using 
NanoTemper’s Protein Labeling Kit RED. The concentration of labeled protein was kept 
constant at ∼100 nM. The ligand to protein concentration ratio was tested in the range of 0.01 
to 100. Samples were loaded into K002 Monolith™ NT.115 Standard Treated Capillaries. 
After a short incubation period, MST analysis was performed using the Monolith NT.115 
(NanoTemper Technologies). All numerical models were fitted to experimental data using the 
NT Analysis 1.5.41 software (NanoTemper Technologies). Presented results are weighted-
averages of at least 5 independent experiments. 
MST-derived Kdiss values were converted to inhibitory activities, assuming competition 
between the halogenated ligand and ATP, according to Equation 3 [95]: 









ATPdiss
tot
liganddiss
K
ATP
KIC
,
,50
][
1
         (3) 
 
3. Results  
3.1. Fluorescence-monitored melting of hCK2α complexes (DSF). 
Inspection of the ensemble of complexes of human CK2α with TBBt, which were modeled 
by homology on the basis of TBBt bound to maize CK2α (PDB: 1j91) clearly indicates that 
Tyr50 is the major sensor for binding at the ATP-binding site of TBBt and its homologues, 
since its fluorescence may be quenched directly by the ligand located within a distance of 7-9 
Å (see Figure 1). The distance of the ligand located at the ATP-binding site from the 
remaining Tyrosine residues exceeds 12.5 Å, so that ligand-induced changes in their 
fluorescence are negligible. Moreover, the next two closest tyrosine residues (Tyr39 and 
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Tyr125) are shielded from the ligand by electron densities of the β-sheets that border the 
ATP-binding site.  
Figure 1. 
The changes in the distance and orientation of the Tyr50 phenol ring relative to the ligand 
strongly depend on the spatial organization of the glycine-rich loop, the conformation of 
which is highly diversified in accessible structures of CK2α [96], and on the location of the 
ligand at the ATP-binding site, which also varies in complexes with protein kinases [36]. This 
structural flexibility renders Tyr50 sensitive, not only to the population of the bound ligand, 
but also to any changes in its orientation and/or its ionic state.  
Thermal stability of hCK2α and its 1:1 and 10:1 complexes (ligand to protein concentration 
ratio) with all nine halogenated benzotriazoles was studied with the aid of fluorescence-
monitored thermal denaturation. The ATP-bound form of the protein was tested as the 
reference. None of the ligands interact with an unfolded form of hCK2α, as indicated by a 
common trend of temperature-dependence of fluorescence intensity observed for the high-
temperature region (T > 60 °C in Figure 2).  
Inspection of the denaturation curves shows that the nine ligands cluster into three groups 
(see Fig. 2A, B). At 20 °C, when the protein is folded, four of them, namely TBBt, 4,5,6-
Br3Bt, 5,6-Br2Bt and 5-BrBt, strongly quench tyrosine fluorescence, even at a 1:1 protein to 
ligand ratio (Figure 2A). The mid-point temperature of complexes with these ligands, Tm, is 
also increased (Table 1, Figure 2D), indicating that all of them bind efficiently to hCK2α at 
submicromolar concentrations, and the structure of the protein is visibly stabilized when each 
of these ligands is bound. All ligands, with the exception of 5-BrBt, carry two bromine atoms 
at C(5)/C(6) of the benzene ring of benzotriazole (see Scheme 1). Since all these ligands 
similarly quench tyrosine fluorescence, it might be deduced that each of them binds to hCK2α 
in an almost identical orientation, putatively close to that at which TBBt is found in the 
crystal structure of maize CK2α (PDB: 1j91) [57], or modeled in the complex with human 
CK2α (Figure 1).  
The next three ligands, 4,5,7-Br3Bt, 4,6-Br2Bt and 4,5-Br2Bt, also visibly shift Tm, but to 
a lesser extent than for the first group of ligands. Moreover, they affect tyrosine fluorescence 
only at higher ligand excess (Figure 2B), and the observed tyrosine fluorescence quenching is 
weaker than that for TBBt. Both effects indicate that all three bind to hCK2α more weakly 
than any from the previous group. An analogous trend in fluorescence quenching has been 
recently observed for TBBt and TBBz, which bind to maize CK2α in different orientations 
(see structures based on PDB: 1j91 [57] and PDB: 2oxy [91] in Figures 6A and 6B, 
respectively), and also for their derivatives with bromine at C4 replaced by a methyl group 
[63]. It may thus be hypothesized that 4,5-Br2Bt, 4,6-Br2Bt, and most likely 4,5,7-Br3Bt, 
bind to CK2α in different orientations than TBBt. All these ligands carry only a single 
bromine atom at C(5)/C(6).  
 10 
Finally, in the entire range of scanned temperatures, virtually no changes in fluorescence 
are observed for ligands halogenated solely at sites proximal to the triazole ring, C(4) and/or 
C(7): 4,7-Br2Bt and 4-BrBt. This indicates that these two compounds virtually do not interact 
with hCK2α.  
Figure 2. 
Contrary to the strongly binding halogenated benzotriazoles (TBBt, 4,5,6-Br3Bt, 5,6-Br2Bt 
and 5-BrBt), ATP only minimally changes the fluorescence of the folded form of hCK2α, 
albeit at a higher concentration of 2.5 μM it increases thermal stability of the protein by ~2 °C 
(Figure 2C). 
The observed ATP-induced increase in the thermal stability of hCK2α shows that all 
ligands that shift unfolding temperature by less than 2 °C cannot compete with ATP, and thus 
cannot be regarded as putative CK2α inhibitors. In this context, only the first group of 
halogenated benzotriazoles (TBBt, 4,5,6-Br3Bt, 5,6-Br2Bt and 5-BrBt) may be considered as 
potential inhibitors.  
3.2. Differential Scanning Calorimetry (DSC) 
DSC was applied to monitor thermal denaturation of free hCK2α and its nine 1:1 
complexes with halogenated benzotriazoles. After correction for the low- and high-
temperature asymptotes, the two thermodynamic parameters could be estimated directly from 
the thermograms: Tm as the location of the maximum, and ΔHcal as the area under the heat-
flow curve (Figure 3A). As expected, all these temperatures agree with the DSF-derived 
temperatures for denaturation of the ligand-protein complexes (Figure 3B). The change in 
heat capacity associated with protein unfolding (ΔCp) was roughly estimated as the difference 
between the low- and high-temperature heat-flow asymptotes at Tm. The resulting 
thermodynamic parameters are presented in Table 1. 
Figure 3. 
All complexes with ligands carrying at least one bromine at C(5)/C(6) are much more 
stable (i.e. display higher Tm and ΔGunf values) than free hCK2α. And the higher the Tm with a 
given ligand, the more efficiently it binds, as indicated by the values of ΔGbind and Kdiss 
extrapolated to 25 °C. Unfortunately, extrapolation of the other thermodynamic parameters 
related to ligand binding are heavily biased, due to possible temperature-dependence of ΔCp 
(see Equation 2). Predominance of the heat of protein unfolding (Hunf) over the heat of 
binding of small ligands (ΔHbind = -ΔHdiss) precludes reliable estimates of heat of binding. 
Moreover, the contribution of the temperature-dependent entropy of hydration for a highly 
hydrophobic ligand to the Free Gibbs Energy of binding, estimated from DSC, may also 
significantly contribute to lowering of the apparent DSC-derived dissociation constants. 
However, the relation between ligand-induced changes in the unfolding temperature (Tm) and 
the apparent heat of ligand dissociation at Tm (ΔΔHcal = ΔHcal - ΔHcal,apo) clearly shows that 
the enthalpic contribution to the free energy of binding for the four most potent ligands 
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(TBBt, 4,5,6-Br3Bt, 5,6-Br2Bt and 5-BrBt) is visibly larger than that for the other ligands 
(Figure 4A), and a positive correlation between ΔΔHcal and ΔTm points, at least at 50 °C, to a 
favorable enthalpic contribution to the free energy of binding. Moreover, the heat of 
dissociation for TBBt, 4,5,6-Br3Bt, 5,6-Br2Bt and 5-BrBt clearly decreases when the pKa of 
the ligand increases, while for the others the changes are much more moderate (Figure 4B). 
This agrees with the observed preference of CK2α for hydrophobic anions [91]. 
Figure 4. 
The foregoing, together with the variations in quenching of tyrosine fluorescence (Figure 
2), and molecular modeling (Figure 1), support binding of TBBt, 4,5,6-Br3Bt, 5,6-Br2Bt and 
5-BrBt to hCK2α at the ATP-binding site in an orientation that enables short-range 
electrostatic interactions between the triazole ring of ligand and a proximal side-chain of 
Lys68 (Figure 5A). Other orientations of the ligand, some of which are shown in Figures 5B 
and 5C, preclude efficient electrostatic interactions, resulting in a substantial decrease of the 
heat of ligand binding and, in parallel, the heat effect is less sensitive to ligand electronic 
properties. This agrees with the data for 4-BrBt, 4,5-Br2Bt, 4,6-Br2Bt, 4,7-Br2Bt and 4,5,7-
Br3Bt, the heat of dissociation for which does not depend on their pKa, and the value of ~50 
kJ/mol may reflect the enthalpic effect of a release of some water molecules upon ligand 
binding. Since the enthalpy of formation of an individual hydrogen bond in bulk water has 
been estimated as 15 kJ/mol [97], the observed gain of 50-75 kJ/mol corresponds to possible 
formation of additional 3-5 hydrogen bonds involving water molecules released to bulk 
solvent upon ligand binding.  
Figure 5. 
3.3. Microscale Thermophoresis (MST) 
MST, like Isothermal Titration Calorimetry (ITC), also supports determination of binding 
affinities at constant temperature, albeit both methods substantially differ in the required 
sample concentrations. Another advantage of MST is the relatively small sample consumption 
of measurements carried out in microcapilaries, but the protocol of sample preparation 
implies a short preincubation of protein-ligand solutions. The MST method was used to verify 
results obtained by temperature-scanning methods, and permitted direct determination at 
25 °C of binding affinities for the seven most potent ligands (see Figure 6 and Table 1).  
Figure 6. 
The order of the estimated dissociation constants (Kdiss) determined by MST agrees with 
DSC-derived data extrapolated to 25 °C, but the latter values are systematically 
overestimated. This is most probably due to an eventual uncontrolled temperature-dependence 
of ΔCp, the contribution of which may differ substantially for each ligand. However, together 
they tend to compensate, resulting in the general trend presented in Figure 7A.  
Figure 7. 
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MST-derived dissociation constants were also converted to IC50 data according to Equation 
3, using [ATPtot] = 10 µM [61] and measured Kdiss for ATP of 4.3±1.8 µM. The MST-derived 
IC50 values are in full accord with inhibitory activities determined by biochemical assay [61]. 
It should however be noted that MST-derived dissociation constants may be slightly 
underestimated due to possible non-specific ligand binding, which was occasionally observed 
at high excess of ligand.  
 
4. Discussion 
Comparison of binding affinities obtained by different methods shows that, despite some 
discrepancies between methods, the ordering of ligands based on their potency of binding is 
consistent with their inhibitory activities (see Figures 7B, 8A and 8B). It follows that DSF 
measurements with a 10-fold ligand excess, followed by DSC analysis of 1:1 complexes, 
recently suggested to be optimal in drug screening [75, 98], effectively screens for efficient 
CK2α inhibitors. However, MST results may be used alternatively to the biochemical assay 
[99], as shown in Figure 7B.  
Figure 8. 
The systematic deviations observed for 5-BrBt must be assigned directly to the difference 
in the experimental setups of thermodynamics (pH = 8) and biochemical (pH = 7.5) 
approaches, while 5-BrBt at pH 7 binds substantially weaker. This difference in solvent pH is 
critical for the ionic state of this ligand, the pKa for which equals 7.55. This discrepancy 
points again to predominance of electrostatic interactions in binding of TBBt derivatives at 
the ATP-binding site of CK2α.  
MST-derived binding affinities of halogenated benzotriazoles are correlated with their 
aqueous solubility. This implies that ligand-solvent interactions are the driving force 
contributing to the apparent free energy of ligand-protein interactions. The observed three 
general "partial"-correlation lines must be the result of substantial differences in protein-
ligand interactions with an eventual contribution of ligand-ligand interactions in the solid-
state. The systematic decrease of binding affinities observed for 4-BrBt, 4,5-Br2Bt, 4,6-
Br2Bt, 4,7-Br2Bt should be assigned to variation in electrostatic interactions between the 
dissociated triazole ring of the ligand and the side-chain of Lys68 that arise from the different 
locations of these ligands at the ATP-binding site (Figure 5) deduced from DSF and DSC 
data. The observed difference of approximately 20 kJ/mol (large arrow in Figure 9) is in 
accord with the reported contribution of individual salt-bridges to the Gibbs' free energy [8]. 
The internal variance in strongly binding ligands of ~10 kJ/mol (TBBt, 4,5,6-Br3Bt, 5,6-
Br2Bt, 5-BrBt, and most likely 4,5,7-Br3Bt) must consequently be attributed to other types of 
specific ligand-protein interactions, including the eventual contribution of halogen bonding 
observed in the crystal structure of TBBt bound to maize CK2α [36]. 
Figure 9. 
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Figure captions: 
Figure 1. Orthogonal views demonstrating location of Tyrosine residues proximal to TBBt 
bound at the ATP-binding site of human CK2α. Tyr50, which should be the most sensitive to 
ligand binding, is denoted by a black arrow, while TBBt is represented by vdW spheres. The 
ensemble of structures was modeled by homology, based on the reported structure of TBBt 
bound to maize CK2α (PDB: 1j91 [57]) and the highest-resolution structures of human CK2α 
(PDB: 3at2 [82], 3bqc [83], 3h30 [84], 3nsz [85], 3pe1 [86], 3war [87], 4kwp [88]).  
 
Figure 2. Impact of binding of halogenated benzotriazoles on the thermal stability of hCK2α 
monitored by tyrosine fluorescence for 1:1 (A) and 10:1 (B) ligand to protein ligand ratios. As 
the reference the effect of ATP at 1:1 and 10:1 excess on the CK2α thermal stability is 
presented (C, empty and solid squares, respectively). The unfolding temperatures (D) were 
estimated for each ligand at 1:1 (black diamonds) and 10:1 (open diamonds) concentration 
ratios according to Equation 1. 
 
Figure 3. DSC heat-flow thermograms for hCK2α and its 1:1 complexes with halogenated 
benzotriazoles (A), and the comparison of DSC-derived temperatures of thermal unfolding 
with those determined using DSF (B). 
 
Figure 4. Relation between DSC-derived heat for dissociation (ΔΔHcal) and (A) shift in the 
temperature of thermal denaturation (ΔTm), and (B) pKa for dissociation of the free ligand in 
aqueous medium (B).  
 
Figure 5. View of the possible orientations of TBBt-like ligand at the ATP binding site of 
hCK2α, locations of which were adopted from known structures of the complexes of maize 
CK2α with TBBt (A), 4,5,6,7-tetrabromo-1H-benzimidazole (B) and 3,4,5,6,7-pentabromo-
1H-indazole (C), which are the closest structural analogues of TBBt. Side-chains of Lys68 
and Asp175, which are responsible for electrostatic interactions with the ligand, together with 
Tyr50, which senses ligand binding, are represented in sticks model. 
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Figure 6. MSC-derived pseudotitration data for binding of halogenated benzotriazoles to 
hCK2α.  
 
Figure 7. Correlation between dissociation constants, Kdiss, determined for the binding of 
halogenated benzotriazoles to hCK2α, using MST with DSC-derived data extrapolated to 25 
°C (A). The inhibitory activities predicted from MST data according to equation 3 are 
compared with previously determined IC50 data (B). 
 
Figure 8. Ordering of nine halogenated benzotriazoles by their strength of binding to hCK2α 
compared with the IC50 data for DSF-derived mid-point temperatures (A) and DSC-derived 
dissociation constants (B).  
 
Figure 9. Relation between DSC-derived free energy for binding of halogenated ligands to 
hCK2α and their solubility in aqueous medium. 
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